"They found that almost one half of trials had no publically available results at 3 years
after completion."
"The consequences of nonreporting study results—in particular, those from clinical trials with statistically nonsignificant
findings or where significant toxicities are identified which are more likely to remain unpublished7—have far reaching effects."
And importantly: "Finally, study investigators must remember their commitment to research participant volunteers as well as future patients
to see complete pictures of oncologic drugs."
Hi Martha, where are you being treated? After 5.5 years I had a new primary that grew lightning fast. I was worked up in San Diego and MDA. My tumor this time was also the aggressive sarcamatoid. I think I spelled it right. That thing came back 3 days after my first chemo. In the same place as the lumpectomy. Shocked all. So I had an immediate left breast masectomy and nodes. About 3 week went by between the last physical exam and when chemo started. I also had a mediastinal node biopsied as 3 were enlarged. The one the biopsied was negative. I'm on Ixempra and Xeloda chemo. I'm very very interested in this trial or whatever you call it. I may need more. Appreciate knowing where you go. Your doc name. Thank you. Best of all luck.
Advances in the systemic treatment of triple-negative breast cancer
Triple-negative breast cancer constitutes a heterogeneous group of
malignancies that are often aggressive and associated with a poor
prognosis. Molecular characterization, while not a standard of care, can
further subtype triple-negative breast cancer and provide insight into
prognostication and behaviour. Optimal chemotherapy regimens have yet to
be established; however, there have been advances in the systemic
treatment of triple-negative breast cancer in the neoadjuvant, adjuvant,
and metastatic settings. In this review, we discuss evidence for the
potential benefit of neoadjuvant platinum-based chemotherapy, adjuvant
combination chemotherapy with weekly paclitaxel, and BRCA
mutation–directed therapy in the metastatic setting. The role for
adjuvant capecitabine in patients who do not achieve a pathologic
complete response with neoadjuvant chemotherapy is reviewed. Future
directions and data concerning novel targeted agents are reviewed,
including the most recent data on parp [poly (adp-ribose) polymerase] inhibitors, antiandrogen agents, and immunotherapy.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot delete your posts in this forum You cannot edit your posts in this forum You cannot create polls in this forum You cannot vote in polls in this forum